Implications for Practice
HPV-associated malignancies, HPV-associated cancers, anogenital malignancies, prolonged disease, Infection
ONCOGENESIS, PENILE CANCERS, INFECTION
Infection with human papillomavirus drives oncogenesis in the majority of cervical, anal, and penile cancers. Anti-tumor activity with anti-PD-(L)1 antibodies as monotherapy in patients with advanced HPV-associated cancers is modest. This study demonstrated prolonged disease control using combination immunotherapy with a therapeutic HPV-16/HPV-18 DNA vaccine and IL-12 adjuvant in some patients with advanced HPV-associated anogenital malignancies. A minority of patients with HPV-associated cancers experienced durable clinical benefits with durvalumab and MEDI0457 that exceeded one year. Further understanding of immune signatures associated with response to immunotherapy combinations may direct precision approaches of future studies for HPV-associated malignancies.